What is the recommended diagnostic workup and treatment for gastric MALT lymphoma?

Gastric MALT Lymphoma: Diagnostic Workup and Treatment

All patients with gastric MALT lymphoma should receive H. pylori eradication therapy as first-line treatment regardless of H. pylori status or disease stage, using PPI-based triple therapy with clarithromycin plus amoxicillin or metronidazole for 10-14 days. 1

Diagnostic Workup

Initial Endoscopic Evaluation

• Perform esophagogastroduodenoscopy (EGD) with multiple biopsies from each gastric region (antrum, body, fundus), duodenum, gastroesophageal junction, and any abnormal-appearing areas 1
• Take deep, repeated biopsies since gastric MALT lymphoma often shows multifocal distribution with variable endoscopic appearance (erosion, erythema, discoloration, ulcer, subepithelial lesion) 2
• Endoscopic ultrasound (EUS) is mandatory to assess gastric wall infiltration depth and regional lymph nodes—this predicts response to H. pylori eradication 1

Staging Workup

Complete the following studies 1:

• History and physical examination focusing on lymph node regions, eye, ENT areas, liver, and spleen
• Complete blood count and biochemistry (renal/liver function, LDH, β2-microglobulin)
• Serum protein immunofixation
• HIV, HCV, and HBV serology
• CT chest, abdomen, and pelvis—this is optimal initial imaging 3
• Bone marrow aspirate and biopsy 1

The evidence shows that for superficial gastric MALT lymphoma, lymph node metastasis occurs in only 3.6% of cases, with abdominal CT detecting 2.9% and chest CT detecting an additional 1.5% 3. Therefore, both abdominal and chest CT are recommended as optimal initial workup.

Treatment Algorithm

Stage I-II Disease (Localized)

H. pylori-Positive Patients

1. Administer H. pylori eradication therapy with PPI plus clarithromycin-based triple therapy (with amoxicillin or metronidazole) for 10-14 days 1

2. Confirm eradication with urea breath test or monoclonal stool antigen test at least 6 weeks after therapy and at least 2 weeks after PPI withdrawal 1

3. If eradication fails, attempt second-line triple or quadruple therapy 1

4. Repeat EGD with biopsies at 3-6 months after successful eradication 1

5. Wait up to 12 months for complete remission even if histological residual lymphoma persists, provided clinical and endoscopic remission is achieved with successful H. pylori eradication 1

Critical caveat: Molecular persistence of monoclonal B-cells frequently occurs after histological regression and does not require additional treatment 1

H. pylori-Negative Patients

1. Still administer H. pylori eradication therapy since occasional responses occur (possibly due to false-negative testing or other Helicobacter species) 1

2. Repeat EGD at 2-3 months after antibiotics 1

3. If no lymphoma regression at 2-3 months, proceed to radiotherapy (24-30 Gy to stomach and perigastric nodes over 3-4 weeks) 1

Non-Responders to Eradication Therapy

For patients with persistent lymphoma after eradication:

Localized disease treatment options:

• Radiotherapy is preferred (24-30 Gy involved-field) 1
• Alternative: Chlorambucil or other alkylating agent ± rituximab when radiotherapy not feasible 1

Important: Patients with t(11;18) translocation will likely not respond to alkylating agents alone 1

Stage IV Disease (Disseminated)

1. Administer H. pylori eradication if infection present 1

2. Asymptomatic patients: Watch-and-wait with EGD/biopsies and abdominal ultrasound every 6 months 1

3. Symptomatic patients (overt progression, bulky disease, impending organ damage):

   • Rituximab plus chemotherapy (preferred regimen: rituximab plus chlorambucil based on randomized data) 1
   • Alternative regimens: rituximab-bendamustine, rituximab monotherapy 1
   • Reserve aggressive anthracycline-containing regimens (R-CHOP) only for histological transformation 1

Avoid purine analogues (fludarabine, cladribine) when possible due to increased risk of secondary myelodysplasia 1

Follow-Up Strategy

After Complete Remission

• EGD with biopsies every 6 months for 2 years, then every 12-18 months 1
• Long-term surveillance is essential as gastric adenocarcinoma risk is six-fold higher than general population 4

Persistent Minimal Residual Disease

• If asymptomatic with stable disease: EGD with biopsies every 3-6 months 1
• Watch-and-wait is safe for persistent but stable residual disease without gross endoscopic tumor or distant dissemination 4

Critical Pitfalls to Avoid

1. Do not withhold H. pylori eradication in H. pylori-negative patients—still administer it 1

2. Do not rush to additional treatment if histological residual persists but clinical/endoscopic remission achieved—wait 12 months 1

3. Surgery has no role in initial treatment and impairs quality of life 1

4. Do not use alkylating agents alone in patients with t(11;18) translocation 1

5. Transient histological relapses on follow-up biopsies are often self-limiting and only constitute true relapse if sustained and progressive 4